U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28O2
Molecular Weight 324.4565
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETONOGESTREL

SMILES

[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=GCKFUYQCUCGESZ-BPIQYHPVSA-N
InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021529s004lbl.pdf

Etonogestrel, also known as 11-methylenelevonorgestrel and 3-keto-desogestrel, is a steroidal progestin used in hormonal contraceptives, most notably the subdermal implants Nexplanon and Implanon and the vaginal ring NuvaRing. Etonogestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Etonogestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. Etonogestrel binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like etonogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
IMPLANON

Approved Use

IMPLANON™ (etonogestrel implant) is indicated for women for the prevention of pregnancy.

Launch Date

2006
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.59 ng/mL
75 μg 1 times / day multiple, oral
dose: 75 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.097 ng × h/mL
75 μg 1 times / day multiple, oral
dose: 75 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29.2 h
75 μg 1 times / day multiple, oral
dose: 75 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ETONOGESTREL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
ETONOGESTREL blood
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Disc. AE: Menstrual irregularity, Emotional lability...
AEs leading to
discontinuation/dose reduction:
Menstrual irregularity (11.1%)
Emotional lability (2.3%)
Weight increase (2.3%)
Headache (1.6%)
Acne (1.3%)
Depression (1%)
Sources:
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Other AEs: Headache, Vaginitis...
Other AEs:
Headache (24.9%)
Vaginitis (14.5%)
Weight increase (13.7%)
Acne (13.5%)
Breast pain (12.8%)
Abdominal pain (10.9%)
Pharyngitis (10.5%)
Leukorrhea (9.6%)
Influenza-like symptoms (7.6%)
Dizziness (7.2%)
Dysmenorrhea (7.2%)
Back pain (6.8%)
Emotional lability (6.5%)
Nausea (6.4%)
Pain (5.6%)
Nervousness (5.6%)
Depression (5.5%)
Hypersensitivity (5.4%)
Injection site pain (5.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Depression 1%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Acne 1.3%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Headache 1.6%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Menstrual irregularity 11.1%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Emotional lability 2.3%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Weight increase 2.3%
Disc. AE
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Pharyngitis 10.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Abdominal pain 10.9%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Breast pain 12.8%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Acne 13.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Weight increase 13.7%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Vaginitis 14.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Headache 24.9%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Injection site pain 5.2%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Hypersensitivity 5.4%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Depression 5.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Nervousness 5.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Pain 5.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Nausea 6.4%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Emotional lability 6.5%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Back pain 6.8%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Dizziness 7.2%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Dysmenorrhea 7.2%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Influenza-like symptoms 7.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Leukorrhea 9.6%
70 ug 1 times / day steady, subdermal
Recommended
Dose: 70 ug, 1 times / day
Route: subdermal
Route: steady
Dose: 70 ug, 1 times / day
Sources:
healthy, adult
n = 942
Health Status: healthy
Age Group: adult
Sex: F
Population Size: 942
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes
yes (co-administration study)
Comment: Coadministration of Efavirenz (CYP3A4 inducer) decreased Etonogestrel plasma concentration one week after implant insertion by 84%.
Page: 5, 15, (ClinPharm) 14, 25
PubMed

PubMed

TitleDatePubMed
A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.
2003 Aug
[A randomized study comparing the efficacy and bleeding pattern of Implanon and Norplant hormonal contraceptive implant].
2003 Jul
The impalpable Implanon: a case report.
2003 Jul
Spontaneous snapping of an Implanon in two halves in situ.
2003 Oct
[Acne vulgaris in connection with the use of progestagens in a hormonal IUD or a subcutaneous implant].
2003 Oct 25
[Vaginal contraception: new form of administration of hormonal contraception].
2003 Oct 25
Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids--a randomized comparative study.
2003 Sep
Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
2004
New delivery systems in contraception: vaginal rings.
2004 Apr
Treatment of endometriotic catamenial haemoptysis with etonogestrel subdermal implant.
2004 Apr
Pharmacological profile of progestins.
2004 Apr 15
Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group.
2004 Dec
Implanon and medical indemnity: a case study of risk management using the Australian standard.
2004 Jul 19
Implanon use in Thai women above the age of 35 years.
2004 Jun
Experience with Implanon in a northeast London family planning clinic.
2004 Mar
The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
2004 May
Implanon studies conducted in Indonesia.
2004 Nov
Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception.
2004 Nov
A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function.
2004 Sep
[Two patients with a non-palpable, subcutaneously implanted contraceptive].
2004 Sep 4
Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
2005
Contraceptive implants.
2005 Apr
Clinical challenge with Implanon removal: a case report.
2005 Apr
Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia.
2005 Apr
Effect of Implanon on insulin resistance in women with Polycystic Ovary Syndrome.
2005 Apr
Ultrasound localisation of non-palpable Implanon.
2005 Apr
A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception.
2005 Apr
Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners.
2005 Apr
Australian women's experience with Implanon.
2005 Aug
Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis.
2005 Dec
Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.
2005 Dec
Migration of implanon: two case reports.
2005 Jan
Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon).
2005 Jan
Self removal of Implanon: a case report.
2005 Jul
FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence.
2005 Jul
The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.
2005 Jul
Gateways to clinical trials.
2005 Jun
One year study of Implanon on the adverse events and discontinuation.
2005 Mar
Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
2005 Mar
[Preliminary results from the OPNI observatory: long-term follow-up of a cohort of women using the progestagen contraceptive implant Implanon].
2005 May
Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
2005 May
How to remove impalpable Implanon implants.
2005 Oct
An assessment of the first 3 years' use of Implanon in Luton.
2005 Oct
[Ectopic pregnancy with etonogestrel contraceptive implant (Implanon): first case].
2005 Oct
[Hormonal contraception for males--an option for adolescents?].
2005 Oct
Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women.
2005 Sep
Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant.
2005 Sep
A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.
2006 Jan
Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.
2006 Jan
A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive.
2006 Jan
Patents

Sample Use Guides

Usual Adult Dose for Contraception One 68 mg implant inserted subdermally. The implant should not be left in place more than three years.
Route of Administration: Transdermal
Etonogestrel (1716 pg/mL) significantly altered antiretroviral uptake across THP-1, BC-3 (CD8+) cell lines, incubated for one hour with tenofovir and emtricitabine to assess uptake except
Name Type Language
ETONOGESTREL
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ETONOGESTREL [MI]
Common Name English
ORG 3236
Code English
etonogestrel [INN]
Common Name English
DESOGESTREL IMPURITY D
EP  
Common Name English
13-Ethyl-17-hydroxy-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-3-one
Common Name English
ETONOGESTREL [ORANGE BOOK]
Common Name English
DESOGESTREL IMPURITY D [EP IMPURITY]
Common Name English
ETONOGESTREL [USAN]
Common Name English
NUVARING COMPONENT ETONOGESTREL
Common Name English
IMPLANON
Brand Name English
ORG-3236
Code English
ETONOGESTREL [MART.]
Common Name English
ETONOGESTREL [VANDF]
Common Name English
DESOGESTREL RELATED COMPOUND C [USP-RS]
Common Name English
ETONOGESTREL [USP-RS]
Common Name English
13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol-3-one
Systematic Name English
18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-11-METHYLENE-
Common Name English
DESOGESTREL RELATED COMPOUND C
USP-RS  
Common Name English
Etonogestrel [WHO-DD]
Common Name English
ETONOGESTREL COMPONENT OF NUVARING
Common Name English
Classification Tree Code System Code
NDF-RT N0000011301
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
WHO-ATC G03AC08
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
NCI_THESAURUS C776
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
WHO-VATC QG03AC08
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
LIVERTOX 388
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
NDF-RT N0000175602
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1268783
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
ChEMBL
CHEMBL1531
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
DRUG CENTRAL
1110
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
CHEBI
50777
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
DAILYMED
304GTH6RNH
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
RXCUI
14584
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY RxNorm
IUPHAR
7590
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
LACTMED
Etonogestrel
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
NCI_THESAURUS
C47528
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
RS_ITEM_NUM
1173268
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
ALTERNATIVE
ECHA (EC/EINECS)
258-936-2
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
INN
6832
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
MERCK INDEX
m5198
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY Merck Index
EVMPD
SUB07335MIG
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
FDA UNII
304GTH6RNH
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
DRUG BANK
DB00294
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
CAS
54048-10-1
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
SMS_ID
100000082090
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID9046782
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
WIKIPEDIA
ETONOGESTREL
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY
PUBCHEM
6917715
Created by admin on Sat Dec 16 17:53:31 GMT 2023 , Edited by admin on Sat Dec 16 17:53:31 GMT 2023
PRIMARY